Volume 6.44 | Nov 13

Mammary Cell News 6.44 November 13, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Mitochondrial MKP1 Is a Target for Therapy-Resistant HER2-Positive Breast Cancer Cells
Cell survival regulated by mitochondrial MKP1 was responsible for conferring radioresistance in HER2-overexpressing breast cancer cells, due to the fact that MKP1 serves as a major downstream effector in the HER2-activated RAF-MEK-ERK pathway. [Cancer Res] Abstract
Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture FREE Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

Loss of Giant Obscurins from Breast Epithelium Promotes Epithelial-to-Mesenchymal Transition, Tumorigenicity and Metastasis
Researchers demonstrate that the expression levels and subcellular distribution of giant obscurins are altered in human breast cancer biopsies compared with matched normal samples. Stable clones of non-tumorigenic MCF10A cells lacking giant obscurins fail to form adhesion junctions, undergo epithelial-to-mesenchymal transition and generate >100-μm mammospheres bearing markers of cancer-initiating cells. [Oncogene] Abstract

Involvement of RARRES3 in the Regulation of Wnt Proteins Acylation and Signaling Activities in Human Breast Cancer Cells
Researchers identified a novel regulatory mechanism of Wnt/β-catenin signaling through RARRES3 that targets and modulates the acylation status of Wnt proteins and co-receptor low-density lipoprotein receptor-related protein 6, resulting in the suppression of epithelial-mesenchymal transition and cancer stem cell properties. [Cell Death Differ] Abstract

Endothelial Cells Provide a Notch-Dependent Pro-Tumoral Niche for Enhancing Breast Cancer Survival, Stemness and Pro-Metastatic Properties
Using endothelial cells and breast cancer cell lines MDA-MB231 and MCF-7, scientists developed co-culture systems to study the influence of tumor endothelium on breast tumor development by both in vitro and in vivo approaches. [PLoS One] Full Article

A Biomimetic Collagen Derived Peptide Exhibits Anti-Angiogenic Activity in Triple Negative Breast Cancer
Scientists investigated the application of a mimetic 20 amino acid peptide derived from type IV collagen for treatment of breast cancer. They show that the peptide induced a decrease of proliferation, adhesion, and migration of endothelial and tumor cells in vitro. [PLoS One] Full Article

6,7-Di-O-Acetylsinococuline (FK-3000) Induces G2/M Phase Arrest in Breast Carcinomas through p38 MAPK Phosphorylation and CDC25B Dephosphorylation
Researchers evaluated the cytostatic effect of FK-3000 isolated from Stephania delavayi Diels. against breast carcinoma cell lines MDA-MB-231 and MCF-7. [Int J Oncol] Abstract

Inhibitory Effect of Emodin on Migration, Invasion and Metastasis of Human Breast Cancer MDA-MB-231 Cells In Vitro and In Vivo
Scientists used breast cancer MDA-MB-231 cells and a mouse xenograft model to demonstrate the effect of emodin on the migration, invasion and metastasis of human breast cancer MDA-MB-231 cells and the related mechanisms. [Oncol Rep] Abstract


Insulin-Like Growth Factor-I Inhibition with Pasireotide Decreases Cell Proliferation and Increases Apoptosis in Pre-Malignant Lesions of the Breast: A Phase I Proof of Principle Trial
Insulin-like growth factor I (IGF-I) inhibition by pasireotide, acting through the IGF-1 receptor, was associated with decreased proliferation and increased apoptosis in pre-malignant breast lesions and one ductal carcinoma in situ. [Breast Cancer Res] Abstract | Full Article

Efficacy of Eribulin in Women with Metastatic Breast Cancer: A Pooled Analysis of Two Phase III Studies
Data from two Phase III studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient subgroups, previously treated with an anthracycline and a taxane, benefited from eribulin. [Breast Cancer Res Treat] Full Article

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
Wip1 Phosphatase in Breast Cancer
The authors discuss the recent development in understanding how wild-type p53-induced phosphatase 1 (Wip1) contributes to tumorigenesis with its relevance to breast cancer. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Generex Announces Presentation at the Society for Immunotherapy of Cancer Demonstrating that Induction of Antibody Response in Patients Receiving the AE37 Breast Cancer Vaccine Correlates with Reduced Relapse
Generex Biotechnology Corporation announced a presentation showing that induction of an antibody response to the HER2 target of its AE37 cancer vaccine correlated with a reduction of relapse in breast cancer patients. [Press release from Generex Biotechnology Corporation discussing research presented at the 29th Annual Meeting & Associated Programs of the Society for Immunotherapy of Cancer (SITC), National Harbor]
Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
Oncoethix Starts Phase Ib Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
Oncoethix announced that the first patient has been enrolled in an international, open-label, non-randomized, multicenter Phase Ib trial of OTX015 in advanced solid tumors. [Oncoethix (Business Wire)] Press Release

Regis Chair for Breast Cancer Research Established
Regis Corporation announced that the Masonic Cancer Center, University of Minnesota has established the Regis Chair for Breast Cancer Research. This will help the Masonic Cancer Center attract, retain and support the work of leading breast cancer researchers. [Regis Corporation (PR Newswire Association LLC)]
Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Stem Cell Summit 2014
December 3-5, 2014
San Antonio, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

Professor – Breast/Abdominal Surgery or Gynecology (Fudan University Shanghai Cancer Center)

Postdoctoral Position – Molecular Cancer Biology (Baylor College of Medicine)

Postdoctoral Position – Cancer Metabolism (New York University Langone Medical Center)

Postdoctoral Position – Protein-Protein Interactions in Leukemia and Breast Cancer (University of Dundee)

PhD Position – Protein Interactions in Cancer Regulation (University of East Anglia)

Postdoctoral Fellow – Breast Cancer (University of Texas Health Science Center at San Antonio)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us